Andexanet Alfa

Excerpt

This activity offers clinicians an in-depth review of andexanet alfa, the first FDA-approved recombinant factor Xa protein designed to rapidly reverse the anticoagulant effects of apixaban and rivaroxaban in patients with life-threatening bleeding. As the use of factor Xa inhibitors increases, understanding the role of andexanet alfa in urgent bleeding management has become critical. The activity covers dosing regimens, administration protocols, and important safety considerations, including thrombotic risks and the need for prompt re-initiation of anticoagulation. Special populations, drug interactions (notably with unfractionated heparin), and adverse effect profiles are addressed to support safe clinical decision-making. By engaging in this activity, clinicians enhance their competence in the multidisciplinary management of factor Xa inhibitor–associated bleeding and optimize patient outcomes through evidence-based use of andexanet alfa.